Role of Intestinal Mucosal Barrier in Type 2 Diabetes Mellitus and Research Progress in Chinese Medicine Interventions
Abstract
The intestinal mucosal barrier is closely associated with the occurrence and development of type 2 diabetes mellitus (T2DM). It plays an important role in maintaining the homeostasis of the internal environment and resisting pathogenic invasion by regulating the metabolic homeostasis, immune response, and microbial-host interactions in the human body. According to recent studies, intestinal mucosal barrier dysregulation may constitute a key link in the pathogenesis of T2DM. Herein, we systematically reviewed the mechanisms by which intestinal mucosal barrier damage contributes to the onset of T2DM and the latest advances in modern medical intervention strategies. We also discussed and summarized the latest research findings on using traditional Chinese medicine (TCM) to regulate the intestinal mucosal barrier in the management of T2DM. Currently, the causal relationship and mechanisms linking intestinal mucosal barrier damage to the onset of T2DM remain unclear, and systematic research on the synergistic regulatory mechanisms of approaches integrating TCM and Western medicine is lacking. The approach to manage T2DM through the integration of TCM and Western medicine can provide insights and basis from multiple aspects, such as TCM syndrome differentiation and treatment, balancing drug properties, and multi-targeted therapy. In the future, we should fully leverage the advantages of integrated TCM and Western medicine in treating T2DM and conduct in-depth research focused on the intestinal mucosal barrier, thereby informing evidence-based clinical applications.
Keywords: Intestinal mucosal barrier, Diabetes mellitus, type 2, Medicine, Chinese traditional, Gastrointestinal microbiome, Insulin resistance
Full Text:
PDFReferences
Chinese Diabetes Society, Chinese Medical Association. Chinese guidelines for the prevention and treatment of diabetes (2024 Edition). Chin J Diabetes, 2025, 17(1): 16-139. doi: 10.3760/cma.j.cn115791-20241203-00705.
SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022, 183: 109119. doi: 10. 1016/j.diabres.2021.109119.
CIARAMBINO T, CRISPINO P, LETO G, et al. Microbiota and glucidic metabolism: a link with multiple aspects and perspectives. Int J Mol Sci, 2023, 24(12): 10409. doi: 10.3390/ijms241210409.
LENG Y L, XIE Z Y, GAO H, et al. Exploring the mechanism of traditional Chinese medicine in regulating diabetic pancreatic islet cells fate based on 'Spleen Governing Transportation and Transformation' Theory. J Tradit Chin Med, 2022, 63(16): 1520-1524. doi: 10.13288/j.11-2166/r.2022.16.005.
CHEN Z C, LIN Q N, WANG J X, et al. Relationship between "Nutrients-intestinal Flora" and Type 2 Diabetes Mellitus Based on Theory of "Linkage between Spleen and Small Intestine". Chin J Exp Tradit Med Formulae, 2024, 30(15): 206-214. doi: 10.13422/j.cnki.syfjx.20241790.
ZHANG L, GONG X, ZHANG S, et al. Danshen polysaccharides alleviate AFB1 induced Jejunal injury. Ecotoxicol Environ Saf, 2024, 285: 117115. doi: 10.1016/j.ecoenv.2024.117115.
HUANG H, XIE Y, LI X, et al. Danggui Buxue decoction regulates the immune function and intestinal microbiota of cyclophosphamide induced immunosuppressed mice. Front Pharmacol, 2024, 15: 1420411. doi: 10. 3389/fphar.2024.1420411.
LI Y X, CUI Y K, WANG L, et al. Mechanism of modified Wendan Decoction in improving glucose and lipid metabolism disorders in obese type 2 diabetic rats. Journal of Li-Shizhen Traditional Chinese Medicine, 2024, 35(9): 2126-2129. doi: 10.3969/j.issn.1008-0805.2024.09.17.
HU Z M, LIAO H Y, JIANG S M, et al. Mechanism of Yupingfeng Powder on hepatic insulin resistance in type 2 diabetes mellitus rats by regulating IRS/PI3K/Akt pathway. Chin J Chin Mater Med, 2024, 49(12): 3280-3287. doi: 10.19540/j.cnki.cjcmm.20240220.401.
YANG Y Y, YANG H J, ZHANG L J, et al. Clinical effects of Astragali Radix on patients with type 2 diabetes mellitus of Qi Deficiency Pattern. Chin Tradit Pat Med, 2024, 46(10): 3278-3283. doi: 10.3969/j.issn.1001-1528.2024.10.014.
WU G, XU T, ZHAO N, et al. A core microbiome signature as an indicator of health. Cell, 2024, 187(23): 6550-6565.e11. doi: 10.1016/j.cell. 2024.09.019.
BAARS D P, FONDEVILA M F, MEIJNIKMAN A S, et al. The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes. Cell Host Microbe, 2024, 32(8): 1280-1300. doi: 10.1016/j. chom.2024.07.017.
JU T, BOURRIE B C T, FORGIE A J, et al. The gut commensal Escherichia coli aggravates high-fat-diet-induced obesity and insulin resistance in mice. Appl Environ Microbiol, 2023, 89(3): e0162822. doi: 10.1128/aem.01628-22.
SCHEITHAUER T P M, RAMPANELLI E, NIEUWDORP M, et al. Gut Microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol, 2020, 11: 571731. doi: 10.3389/fimmu.2020. 571731.
ZHAO L, LOU H, PENG Y, et al. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine, 2019, 66(3): 526-537. doi: 10. 1007/s12020-019-02103-8.
DING Y Y, LAN J, FANG Y, et al. Dityrosine aggravates hepatic insulin resistance in obese mice by altering gut microbiota and the LPS/TLR4/NF-κB inflammatory pathway. Mol Nutr Food Res, 2023, 67(22): e2300373. doi: 10.1002/mnfr.202300373.
TILG H, MOSCHEN A R. Microbiota and diabetes: an evolving relationship. Gut, 2014, 63(9): 1513-1521. doi: 10.1136/gutjnl-2014-306928.
MAYORGA-RAMOS A, BARBA-OSTRIA C, SIMANCAS-RACINES D, et al. Protective role of butyrate in obesity and diabetes: new insights. Front Nutr, 2022, 9: 1067647. doi: 10.3389/fnut.2022.1067647.
WANG S, YUAN M, ZHANG L, et al. Sodium butyrate potentiates insulin secretion from rat islets at the expense of compromised expression of β cell identity genes. Cell Death Dis, 2022, 13(1): 67. doi: 10.1038/s41419-022-04517-1.
LEE D H, KIM M T, HAN J H. GPR41 and GPR43: from development to metabolic regulation. Biomed Pharmacother, 2024, 175: 116735. doi: 10. 1016/j.biopha.2024.116735.
Refbacks
- There are currently no refbacks.



